Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) announced that CFO Ross Muken will participate in the J.P. Morgan 50th Annual Global Technology, Media, and Communications Conference in Boston on May 24, 2022. The company's management will also engage in multiple investor meetings during the event. SOPHiA GENETICS is committed to advancing data-driven medicine through its innovative SOPHiA DDM™ Platform, which is utilized by over 790 healthcare institutions globally. For investor inquiries, contact Jennifer Pottage, Head of Investor Relations.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that its SOPHiA DDM™ Platform has successfully analyzed one million genomic profiles, marking a significant achievement in data-driven medicine. This milestone illustrates the platform's rapid growth, having doubled its analyzed profiles in just under two years. The technology is utilized across over 790 healthcare institutions worldwide, enhancing the accuracy of genomic variant detection and facilitating improved patient care. Collaborations, such as with GE Healthcare, further support advancements in cancer treatment by optimizing therapeutic targeting.

SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q1 2022 on May 10, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and future business outlook. The call will be available for live webcasting on the company's Investor Relations website. SOPHiA is committed to data-driven medicine and its SOPHiA DDM™ Platform is utilized by over 790 healthcare institutions worldwide.

SOPHiA GENETICS (Nasdaq: SOPH) reported a 42% year-over-year revenue increase for 2021, totaling $40.5 million. In Q4 2021, revenue reached $10.9 million, up 40% from Q4 2020. The company expanded its customer base, growing total recurring platform customers to 382. Despite strong revenue growth, operating losses increased to $21 million in Q4 and $71.5 million for the full year. The company expects 2022 revenue of $51.5 million to $54 million, reflecting growth of 27% to 33% over 2021. Cash reserves were approximately $265 million as of December 31, 2021.

SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced a letter of intent to collaborate on the co-development of genomic applications aimed at enhancing cancer care. This partnership seeks to improve next-generation sequencing (NGS) research and leverage multimodal data to enhance patient outcomes. The companies plan to utilize Ambry Genetics' TumorNEXT-HRD assessments and Variant Assessment database alongside SOPHiA's cloud-based DDM platform. This collaboration may lead to improved diagnostics by integrating genomics, radiology, and pathology data.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that SOFIVA GENOMICS, a leading genetic testing company in Taiwan, is the first institution in the Asia Pacific to adopt their HRD testing technology. This collaboration focuses on advanced HRD detection using deep learning via the SOPHiA DDM Platform, which enhances cancer research capabilities. The technology has shown to detect more HRR genes compared to alternatives, potentially benefiting 150,000 ovarian cancer patients annually in the region. This partnership aims to improve precision medicine and data ownership for SOFIVA GENOMICS.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that CEO Dr. Jurgi Camblong will speak at the Barclays Global Healthcare Conference on March 16, 2022, at 11:15 a.m. ET. The event will be held at the Loews Miami Beach Hotel, Miami, FL. A live webcast of the session will be available on the investor relations section of the SOPHiA GENETICS website.

This healthcare technology company focuses on data-driven medicine, utilizing its SOPHiA DDM™ Platform to analyze complex data sets for over 790 global healthcare institutions.

SOPHiA GENETICS has launched the SOPHiA DDM HRD Solution, aimed at enhancing cancer research through precise molecular testing. This solution identifies homologous recombination deficiency (HRD) mutations and analyzes genomic instability in tumor samples. Collaborating with AstraZeneca, SOPHiA aims to increase in-house HRD testing across Europe, particularly for advanced ovarian cancer patients. The solution allows labs to retain data ownership while saving time and costs. This innovative approach could significantly improve health outcomes in oncology.

SOPHiA GENETICS (Nasdaq: SOPH) has entered into an agreement with Hiroshima University to enhance molecular profiling for blood cancer through next-generation sequencing (NGS). This initiative aims to integrate NGS testing into routine clinical diagnostics for myeloid neoplasms in Japan. The SOPHiA DDM Platform will facilitate the identification of druggable targets and improve diagnosis accuracy. The partnership aligns with previous collaborations, including a long-term agreement with Hitachi, to expand data-driven medicine in the Japanese healthcare landscape.